About this trial
This project will provide novel data using a large cohort of more than 3000 transplanted patients. Risk and protective factors for SARS-CoV-2 infection and COVID-19 disease severity will be identified. The proportion of patients who develop antibodies after infection will be revealed. In this way the presence of these antibodies can be evaluated as a test for prior infection. Our study additionally will demonstrate how long these antibodies remain present and whether they are protective against a new infection.
Eligibility criteria
Qualifiers
all patients who underwent solid organ or hematopoietic cell transplantation at UZ Leuven and who give informed consent
Disqualifiers
age under 18 years
Trial design
Treatments tested in this trial
- SARS-CoV-2 IgG
Treatment groups
Sponsors and collaborators
Universitaire Ziekenhuizen KU Leuven
Lead sponsor
KU Leuven
Collaborator
Hasselt University
Collaborator
Ziekenhuis Oost-Limburg
Collaborator
Jessa Hospital
Collaborator